MINERVA NEUROSCIENCES, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.54 USD | -1.12% |
|
+6.28% | -58.70% |
| May. 01 | Minerva Neurosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Feb. 27 | Sector Update: Health Care Stocks Ease Late Afternoon | MT |
Presentation Operator MessageOperator (Operator)Welcome to the Minerva Neurosciences Second Qu...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which focused on the development and commercialization of product candidates to treat patients suffering from central nervous system (CNS) diseases. It is engaged in developing roluperidone for the treatment of negative symptoms in patients with schizophrenia and have exclusive rights to develop and commercialize MIN-301 for the treatment of Parkinson's disease. It has also co-developed seltorexant for the treatment of insomnia disorder and adjunctive treatment of the major depressive disorder (MDD). Roluperidone is a compound that blocks serotonin, sigma, and a-adrenergic receptors that are involved in the regulation of mood, cognition, sleep, and anxiety. Roluperidone has been designed to block a specific subtype of serotonin receptor called 5-HT2A. MIN-301 is a soluble recombinant form of the Neuregulin-1b1 (NRG-1b1), protein, for the treatment of Parkinson's disease and for other neurodegenerative disorders.
Calendar
2024-08-04
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
2.569
USD
Average target price
7
USD
Spread / Average Target
+172.51%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -58.70% | 17.96M | |
| +9.18% | 114B | |
| +11.49% | 104B | |
| -13.68% | 22.41B | |
| -1.05% | 22.28B | |
| -5.29% | 19.07B | |
| -38.29% | 18B | |
| -3.75% | 17.89B | |
| +7.86% | 14.28B | |
| +34.73% | 12.55B |
- Stock Market
- Equities
- NERV Stock
- News Minerva Neurosciences, Inc.
- Transcript : Minerva Neurosciences, Inc., Q2 2020 Earnings Call, Aug 03, 2020
